Although some studies have described the pharmacokinetics and pharmacodynamics of donepezil in the peripheral compartment, studies focused on drug transport across the blood-brain barrier are still very rare. To our knowledge, the fluctuation in the cerebrospinal fluid concentration of donepezil after administration of the drug has not been described in the literature so far. We recruited 16 patients regularly taking a standard therapeutic dose of donepezil (10 mg per day). All patients (Caucasian race) were treated for at least three months with a stable dose of 10 mg per day prior to sample collection. Patients were divided into two groups depending on the time of plasma and cerebrospinal fluid sampling: 12 h (n = 9; 4 M/5F aged 78.68 ± 7.35 years) and 24 h (n = 7; 3 M/4F aged 77.14 ± 5.87 years) after donepezil administration. The cerebrospinal fluid sample was collected by standard lumbar puncture technique using a single-use traumatic needle. The samples were analysed on an Agilent 1260 Series liquid chromatograph comprising a degasser, a quaternary pump, a light-tight autosampler unit set, a thermostated column compartment, and a UV/VIS detector. Agilent ChemStation software, the statistical software Prism4, version 5.0 (GraphPad Software, USA), and IBM® SPSS® Statistics were used for the analysis of the results. The difference in plasma concentration of donepezil after 12 h (mean ± SEM; 39.99 ± 5.90 ng/ml) and after 24 h (29.38 ± 1.71 ng/ml) was nonsignificant. In contrast, the donepezil concentration in the cerebrospinal fluid was significantly higher in the 24-h interval (7.54 ± 0.55 ng/ml) compared with the 12-h interval (5.19 ± 0.83 ng/ml, which is ~70 % based on mean cerebrospinal fluid values). Based on these data, it is plausible to predict that donepezil might produce a stronger AChE inhibition in the brain at 24 h compared with 12 h following the administration. This information may help physicians individually adjust the time of drug administration in the patients according to time course of the disease symptoms.

Biomedical Research Center University Hospital Hradec Kralove Hradec Kralove Czech Republic

Department of Neurology 2nd Faculty of Medicine Charles University Prague and Motol University Hospital Prague Czech Republic

Department of Neurology Faculty of Medicine and University Hospital Hradec Kralove Charles University Prague Hradec Kralove Czech Republic

Department of Psychiatry Faculty of Medicine and University Hospital Hradec Kralove Charles University Prague Hradec Kralove Czech Republic

Department of Toxicology and Military Pharmacy Faculty of Military Health Sciences University of Defense in Brno Trebesska 1575 500 01 Hradec Kralove Czech Republic

International Clinical Research Center St Anne's University Hospital Brno Brno Czech Republic

Zobrazit více v PubMed

Amini H, Ahmadiani A. High-performance liquid chromatographic determination of rivastigmine in human plasma for application in pharmacokinetic studies. Iran J Pharm Res. 2010;9:115–121. PubMed PMC

Cummings JL, Geldmacher D, Farlow M, Sabbagh M, Christensen D, Betz P. High-dose donepezil (23 mg/day) for the treatment of moderate and severe Alzheimer’s disease: drug profile and clinical guidelines. CNS Neurosci Ther. 2013;19:294–301. doi: 10.1111/cns.12076. PubMed DOI PMC

Darreh-Shori T, Meurling L, Pettersson T, Hugosson K, Hellström-Lindahl E, Andreasen N, Minthon L, Nordberg A. Changes in the activity and protein levels of CSF acetylcholinesterases in relation to cognitive function of patients with mild Alzheimer’s disease following chronic donepezil treatment. J Neural Transm. 2006;113:1791–1801. doi: 10.1007/s00702-006-0526-2. PubMed DOI

Doody RS, Corey-Bloom J, Zhang R, Li H, Ieni J, Schindler R. Safety and tolerability of donepezil at doses up to 20 mg/day: results from a pilot study in patients with Alzheimer’s disease. Drugs Aging. 2008;25:163–174. doi: 10.2165/00002512-200825020-00008. PubMed DOI

Farlow MR, Salloway S, Tariot PN, Yardley J, Moline ML, Wang Q, Brand-Schieber E, Zou H, Hsu T, Satlin A. Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer’s disease: a 24-week, randomized, double-blind study. Clin Ther. 2010;32:1234–1251. doi: 10.1016/j.clinthera.2010.06.019. PubMed DOI PMC

Giacobini E. Cholinergic foundations of Alzheimer’s disease therapy. J Physiol Paris. 2008;92:283–287. doi: 10.1016/S0928-4257(98)80034-X. PubMed DOI

Hartz AMS, Miller DS, Bauer B. Restoring blood-brain barrier P-glycoprotein reduces brain amyloid in a mouse model of Alzheimer’s disease. Mol Pharmacol. 2010;77:715–723. doi: 10.1124/mol.109.061754. PubMed DOI PMC

Hort J, O´Brien JT, Gainotti G G, Pirttila T, Popescu BO, Rektorova I, Sorbi S, Scheltens P. EFNS guidelines for the diagnosis and management of Alzheimer’s disease. Eur J Neurol. 2010;17(10):1236–1248. doi: 10.1111/j.1468-1331.2010.03040.x. PubMed DOI

Ishiwata K, Kawamura K, Yanai K, Hendrikse NH. In vivo evaluation of P-glycoprotein modulation of 8 PET radioligands used clinically. J Nucl Med. 2007;48:81–87. PubMed

Jelic V, Darreh–Shori T. Donepezil: a review of pharmacological characteristics and role in the management of alzheimer disease. Clin Med Insights Ther. 2010;2:771–788. doi: 10.4137/CMT.S5410. DOI

Kuhl DE, Minoshima S, Frey KA, Foster NL, Kilbourn MR, Koeppe RA. Limited donepezil inhibition of acetylcholinesterase measured with positron emission tomography in living Alzheimer cerebral cortex. Ann Neurol. 2000;48:391–395. doi: 10.1002/1531-8249(200009)48:3<391::AID-ANA17>3.0.CO;2-H. PubMed DOI

McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s disease. Neurology. 1984;34:939–944. doi: 10.1212/WNL.34.7.939. PubMed DOI

Noetzli M, Eap CB. Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer’s disease. Clin Pharmacokinet. 2013;52:225–241. doi: 10.1007/s40262-013-0038-9. PubMed DOI

Ressner P, Hort J, Rektorova I, Bartos A, Rusina R, Linek V, Sheardova K. Recommendations for the diagnosis and management of Alzheimer´s disease and other disorders associated with dementia. Cesk Slov Neurol N. 2008;104:494–501.

Ritchie CW, Ames D, Clayton T, Rosalind L. Metaanalysis of randomized trials of the efficacy and safety of donepezil, galantamine and rivastigmine for the treatment of Alzheimer disease. Am J Geriat Psychiat. 2004;12:358–369. doi: 10.1097/00019442-200407000-00003. PubMed DOI

Sabbagh M, Cummings J. Progressive cholinergic decline in Alzheimer’s disease: consideration for treatment with donepezil 23 mg in patients with moderate to severe symptomatology. BMC Neurol. 2011;11:1. doi: 10.1186/1471-2377-11-21. PubMed DOI PMC

Seltzer B. Donepezil: a review. Expert Opin Drug Metab Toxicol. 2005;1:527–536. doi: 10.1517/17425255.1.3.527. PubMed DOI

Talesa VN. Acetylcholinesterase in Alzheimer’s disease. Mech Ageing Dev. 2001;122:1961–1969. doi: 10.1016/S0047-6374(01)00309-8. PubMed DOI

Tiseo PJ, Rogers SL, Friedhoff LT. Pharmacokinetic and pharmacodynamic profile of donepezil HCl following evening administration. Br J Clin Pharmacol. 1998;46(Suppl 1):13–18. PubMed PMC

Memantine and Its Combination with Acetylcholinesterase Inhibitors in Pharmacological Pretreatment of Soman Poisoning in Mice

The Impact of Dextran Sodium Sulfate-Induced Gastrointestinal Injury on the Pharmacokinetic Parameters of Donepezil and Its Active Metabolite 6-O-desmethyldonepezil, and Gastric Myoelectric Activity in Experimental Pigs

Donepezil and Rivastigmine: Pharmacokinetic Profile and Brain-targeting After Intramuscular Administration in Rats

The Concentration of Memantine in the Cerebrospinal Fluid of Alzheimer's Disease Patients and Its Consequence to Oxidative Stress Biomarkers

Anti-Parkinson Drug Biperiden Inhibits Enzyme Acetylcholinesterase